Accounting & Finance Show Asia 2021: The largest technology event in Asia for accountants and finance professionals

Singapore, Sept 9, 2021 – (ACN Newswire) – On 21-22 September 2021, the Accounting & Finance Show Asia 2021 returns for its 4th edition, bringing together the region’s accounting and finance professionals. In two years of disruption, businesses around the world have adapted quickly to rethink their processes and navigate the challenges. This largest...

Genesys Bolsters Asia Pacific Presence with New Appointments to its Regional Leadership Team Amid Robust Business Momentum in the Region

SINGAPORE, Sep 1, 2021 - (ACN Newswire via SEAPRWire.com) - Genesys(R), a global cloud leader in customer experience orchestration, today announced the appointments of Assaf Tarnopolsky, Senior Vice President and General Manager, APAC, and Stephen Hamill, Vice President, ASEAN and South Asia, to the Asia Pacific leadership team. Gwilym Funnell,...

Shippit Inks Three New Deals with Leading Logistics Providers Janio, FedEx and Qxpress to Strengthen Domestic and International Capabilities

SINGAPORE, Jul 1, 2021 - (ACN Newswire via SEAPRWire.com) - Today, fast-growing e-Commerce fulfilment tech company Shippit announces it has signed three new delivery partner deals with integrated logistics solutions provider Janio, global logistics player FedEx, and e-Commerce logistics expert Qxpress. These deals come as part of Shippit's efforts to...

中基長壽科學獲CS Asia Opportunities Master Fund承配配售股份

HONG KONG, Jun 1, 2021 - (亞太商訊 via SEAPRWire.com) - 中基長壽科學集團有限公司(「中基長壽科學」,連同其附屬公司統稱「集團」;股份代號:0767.HK)宣佈,集團於2021年5月31日交易時段後確認獲CS Asia Opportunities Master Fund(「CS基金」)承配配售股份。CS基金是受開曼群島金融管理局監管之互惠基金,由主要提供資產管理服務的China Silver Asset Management LLC管理及最終控制。中基長壽科學早前宣佈配股及發行認購股份,透過配售代理向不少於六名獨立承配人以配售價每股0.65港元配售最多2.5億股股份,而所有承配人均為獨立第三方。根據配售協定,承配人須就配售予彼等之配售股份遵守12個月禁售期。集資所得款項淨額當中約1.8億港元主要用於集團發展長壽科學業務相關的收購項目,以及用作集團往後的一般營運資金。中基長壽科學董事會主席兼執行董事閆立先生表示﹕「我們很高興獲得機構投資者的信任和支持,此為對中基長壽科學未來發展前景的一份肯定,同時進一步擴大我們的股東基礎。中基長壽科學將繼續加快發展步伐,捕捉在長壽科學領域的機遇,發掘更多潛質優厚的項目,並乘『健康中國』的國家戰略之東風,繼續完善我們的研發實力和為產業鏈升級,逐步實現『讓人類健康長壽』的願景。」關於中基長壽科學集團有限公司中基長壽科學集團有限公司(0767.HK)主要從事長壽科學、借貸、證券及其他投資、金融及投資諮詢,以及物業投資業務。集團是世界領先的長壽科學生態系統平台,致力於人類健康長壽事業。通過五大分部營運,長壽科學研究分部包括NK、CBNK、CAR-NK技術平台、CAR-T技術平台、MSC技術平台、長壽生物製品技術平台等進行研發;長壽醫學檢測分部提供人體健康數據和長壽狀況評估;長壽生物製品分部包括NMN、VC緩釋片等長壽生物製品的生產及銷售;長壽管理分部提供人體健康長壽的科學解決方案;會員分部提供世界長壽科學健康會的建設營運和長壽雲建設營運。有關更多資料,請瀏覽: https://www.irasia.com/listco/hk/zhongjilongevity/ Copyright 2021 亞太商訊. All rights reserved. (via SEAPRWire)